A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells
- PMID: 9685373
- DOI: 10.1074/jbc.273.32.20243
A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells
Abstract
Farnesylation is required for the membrane partition and function of several proteins, including Ras. Farnesyl-protein transferase inhibitors (FTIs) were developed to prevent Ras processing and thus to be effective agents for the treatment of cancers harboring mutated ras. However, FTIs inhibit the growth of most tumor cells and several xenograft models, irrespective of whether they possess mutated ras. Furthermore, the antiproliferative effect is not correlated with inhibition of Ki-Ras processing; tumors with wild type ras are inhibited, and FTIs are not particularly toxic. These data suggest that the mechanism of FTI action is complex and may involve other targets besides Ras. To begin to understand how FTIs work, we investigated the mechanism of growth inhibition. FTI causes G1 arrest in a subset of sensitive lines. This is accomplished by transcriptional induction of p21, which mediates the inhibition of cyclin E-associated protein kinase activity, pRb hypophosphorylation and inhibition of DNA replication. Induction of p21 is p53-dependent; it does not occur in cells with mutant p53 or in cells expressing human papillomavirus E6. However, neither p53 nor p21 are required for inhibition of cell proliferation. FTI still blocks the growth of cells deficient in these proteins. In the absence of p21, G1 block is relaxed, DNA replication is not affected, and cells become polyploid and undergo apoptosis. These results suggest that farnesylated protein(s) may be involved in regulating p53 function and in coordinating entrance into S, and that the consequences of FTI treatment are a function of the other mutations found in the tumor cell.
Similar articles
-
Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines.Mol Pharmacol. 2003 Jan;63(1):159-66. doi: 10.1124/mol.63.1.159. Mol Pharmacol. 2003. PMID: 12488548
-
Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.Oncogene. 1999 Dec 9;18(52):7514-26. doi: 10.1038/sj.onc.1203105. Oncogene. 1999. PMID: 10602510
-
The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines.Exp Cell Res. 2001 Jan 1;262(1):17-27. doi: 10.1006/excr.2000.5076. Exp Cell Res. 2001. PMID: 11120601
-
Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.Oncogene. 2000 Dec 27;19(56):6584-93. doi: 10.1038/sj.onc.1204146. Oncogene. 2000. PMID: 11426643 Review.
-
[Farnesyl transferase inhibitors: one target may be found in another].Med Sci (Paris). 2003 Feb;19(2):211-6. doi: 10.1051/medsci/2003192211. Med Sci (Paris). 2003. PMID: 12836615 Review. French.
Cited by
-
Farnesyltransferase inhibitors: potential role in the treatment of cancer.Drugs. 2001;61(6):723-32. doi: 10.2165/00003495-200161060-00002. Drugs. 2001. PMID: 11398905 Review.
-
Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer.Clin Cancer Res. 2009 Apr 15;15(8):2942-8. doi: 10.1158/1078-0432.CCR-08-2658. Epub 2009 Apr 7. Clin Cancer Res. 2009. PMID: 19351752 Free PMC article. Clinical Trial.
-
(--)-Xanthatin selectively induces GADD45γ and stimulates caspase-independent cell death in human breast cancer MDA-MB-231 cells.Chem Res Toxicol. 2011 Jun 20;24(6):855-65. doi: 10.1021/tx200046s. Epub 2011 May 13. Chem Res Toxicol. 2011. PMID: 21568272 Free PMC article.
-
Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitors.Nat Protoc. 2011 Oct 27;6(11):1775-91. doi: 10.1038/nprot.2011.387. Nat Protoc. 2011. PMID: 22036881 Free PMC article.
-
HOP expression is regulated by p53 and RAS and characteristic of a cancer gene signature.Cell Stress Chaperones. 2017 Mar;22(2):213-223. doi: 10.1007/s12192-016-0755-8. Epub 2016 Dec 16. Cell Stress Chaperones. 2017. PMID: 27987076 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous